


TELECOPIER TRANSMISSION

**BRISTOL-MYERS SQUIBB COMPANY**  
**Legal Division**  
**P.O. Box 5100**  
**5 Research Parkway**  
**Wallingford, CT 06492-7660**

TO: USPTO (Alexandria, VA)
TELECOPIER NO: 9-1-571-273-0546
FROM: James Epperson
TELECOPIER NO: 203-677-6900
TOTAL NUMBER OF PAGES INCLUDING THIS ONE: 5
DATE: 9/1/05

IN RE APPLICATION OF  
CHATURVEDULA, ET AL

EXAMINER: ZINNA NORTHINGTON DAVIS  
ART UNIT: 1625

APPLICATION NO: 10/813,870

FILED: MARCH 30, 2004

FOR: AMIDOHETEROCYCLES AS MODULATORS OF THE MELANOCORTIN-4  
RECEPTOR

DOCKET: CT-2773 NP

SIRS:

Enclosed with this facsimile transmission sheet is the following document:

- (1) Listing of claims in response to Office Action dated 8/29/2005 (Notice of Non-Compliant Amendment) having a due date for reply of 9/29/2005.


James Epperson  
Agent for Applicant  
Reg. No. 52,867  
Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
203-677-6974

USSN 10/813,870

CT-2773 NP


## Amendments to the Claims

1. (original) A compound of Formula I



wherein:

A is hydrogen, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>aminoalkyl, or a heterocycle selected from the group consisting of



W is NR<sup>3</sup>, O, or S;

R<sup>1</sup> is selected from phenyl, naphthyl, benzfuranyl, benzthienyl, and indolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkyl, alkyloxy, cyano, trifluoromethyl, and alkoxy carbonyl;

R<sup>2</sup> is C<sub>1-6</sub>alkyl or C<sub>3-7</sub>cycloalkyl;

R<sup>3</sup> is hydrogen or C<sub>1-6</sub>alkyl;

m is 0, 1, 2, or 3;

n is 1 or 2;

X is CO or SO<sub>2</sub>;

B is selected from C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkylmethyl; C<sub>1-3</sub>methoxyalkyl, and C<sub>1-3</sub>phenoxyalkyl or is selected from phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl,


USSN 10/813,870

CT-2773 NP

oxazolyl, isoxazolyl, benzfuranyl, benzthienyl, indolyl, benzoxazolyl, and indazolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkoxy, hydroxyl, trifluoromethyl, cyano, and  $-N(R^3)_2$ ;


or a pharmaceutically acceptable salt or solvate.

2. (Currently amended) A compound of claim 1 ~~the following formula~~ where the carbon marked with an asterisk is of the (R) stereochemistry.



wherein:

A is hydrogen,  $C_{1-4}$ alkyl,  $C_{1-4}$ aminoalkyl, or a heterocycle selected from the group consisting of



W is  $NR^3$ , O, or S;

$R^1$  is selected from phenyl, naphthyl, benzfuranyl, benzthienyl, and indolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkyl, alkoxy, cyano, trifluoromethyl, and alkoxy carbonyl;

$R^2$  is  $C_{1-6}$ alkyl or  $C_{3-7}$ cycloalkyl;

$R^3$  is hydrogen or  $C_{1-6}$ alkyl;

m is 0, 1, 2, or 3;

n is 1 or 2;

USSN 10/813,870


CT-2773 NP

X is CO or SO<sub>2</sub>;

B is selected from C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkylmethyl, C<sub>1-3</sub>methoxyalkyl, and C<sub>1-3</sub>phenoxyalkyl or is selected from phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, benzfuranyl, benzthienyl, indolyl, benzoxazolyl, and indazolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkoxy, hydroxyl, trifluoromethyl, cyano, and -N(R<sup>3</sup>)<sub>2</sub>;

or a pharmaceutically acceptable salt or solvate.

3. (original) A compound of claim 1 where A is C<sub>1-4</sub>aminoalkyl, or a heterocycle selected from



4. (original) A compound of claim 1 where m is 1 and R<sup>1</sup> is phenyl substituted with 1-2 substituents selected from halo, alkyl, alkyloxy, cyano, carboalkoxy.

5. (original) A compound of claim 1 where X is CO and B is selected from C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkylmethyl, C<sub>1-3</sub>methoxyalkyl, and C<sub>1-3</sub>phenoxyalkyl or is selected from phenyl, pyrazinyl, furanyl, isoxazolyl, and benzthienyl, moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkoxy, hydroxy, trifluoromethyl, cyano, and -N(R<sup>3</sup>)<sub>2</sub>.

6. (original) A compound of claim 1 where n is 1.

7. (currently amended) The compound of claim—7\_\_6: N-[1-[(2R)-3-(4-Chlorophenyl)-2-[[3-(dimethylamino)-1-oxopropyl]amino]-1-oxopropyl]-3-azetidyl]-N-cyclohexyl-3-methyl-butanamide.

8. (original) A compound of claim 1 where n is 2.

9. (cancelled)

10. (currently amended) A compound of claim 9-8 selected from the following group:

(3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[3-[cyclohexyl(5-isoxazolylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;

USSN 10/813,870

CT-2773 NP

(3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(5-isoxazolylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;

(2S)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(1-oxopentyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-Isoquinolinecarboxamide;

(3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(2-furanylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;

N-[1-[(2R)-3-(4-Chlorophenyl)-2-[(3S)-[3-(dimethylamino)-1-oxopropyl]amino]-1-oxopropyl]-3-pyrrolidinyl]-N-cyclohexyl-3-methyl-butanamide; and

(3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(methylsulfonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide.

11. (original) A pharmaceutical composition comprising a therapeutic amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

12. (cancelled)